Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Altay Therapeutics logo — Unlocking Transcription Factors to Address Unmet Medical Nee...

Altay Therapeutics

Unlocking Transcription Factors to Address Unmet Medical Need

Founded 2019 United States San Francisco, United States 6 employees Seed Total: $3.37M Biotechnology, Health Care +3

General Information

Company Name Altay Therapeutics
Founded Year 2019
Location United States San Francisco, United States
Founders / Decision Makers
Team member
Employees 6
Industries Biotechnology, Health Care, Health and Wellness +2
Funding Stage Seed
Business Model B2B
Revenue Model Licensing, Performance Based, Product Sales
Social

BounceWatch is an independent company data service, not affiliated with Altay Therapeutics. To contact Altay Therapeutics, visit altaytherapeutics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Altay Therapeutics compare?

A PDF of Altay Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Altay Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Altay Therapeutics

Altay Therapeutics, headquartered in the United States, is a promising player in the Biotechnology and Life Sciences sectors. Founded in 2019, the company specializes in the development of novel small molecule drugs targeting disease-causing transcription factors, aiming to treat chronic illnesses and cancers.

Their unique platform underscores their strategic differentiation and potential impact within the Health Care and Health and Wellness industries. Altay's slogan, "We develop small molecule drugs targeting disease-causing transcription factors to treat chronic illnesses and cancers," succinctly captures its mission and innovative approach.

The company last received a Seed Round investment of $3.00M on 21 September 2022 from Solve FSHD, indicating strong investor confidence and strategic alignment. As Altay Therapeutics progresses, it is well-positioned to appeal to investors seeking advancements in medical science and biotechnology.

Business keywords: small molecule drugs, drug development, transcription factors, chronic illnesses, cancers, disease treatment, pharmaceuticals, drug targeting, biomedical research

Services & Products

Development of oral transcription factor inhibitors
Drug discovery and development
Precision medicine for underserved diseases

Target Customers

Patients with FSHD Cancer patients Patients with chronic inflammatory diseases Medical researchers

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Seed $3.00M 1
SOLVE FSHD
01 Sep 2022
Seed Undisclosed 1
Tachyon Valley BioLabs
01 May 2022
Seed Undisclosed -
01 Sep 2021
Grant $90.00K -
01 May 2021
Round Undisclosed 1
Creative Destruction Lab
Creative Destruction Lab
01 Jan 2021
Seed $130.00K 1
Y Combinator
Y Combinator
01 Sep 2020
Seed $150.00K -
01 Mar 2020

Altay Therapeutics Alternatives & Competitors

View All Alternatives
Altay Therapeutics vs
Amira Pharmaceuticals
Amira Pharmaceuticals

Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early...

Series B
15 employees
Biotechnology, Health Care
Altay Therapeutics vs
Orbit Discovery
Orbit Discovery United Kingdom

Delivering Peptide Enabled Drug Discovery Solutions

Seed
31 employees
Biotechnology, Health Care
Altay Therapeutics vs
Reborna Biosciences, Inc.
Reborna Biosciences, Inc. Japan

Save the life of rare disease patients and the parents by RNA binding molecules.

Seed
7 employees
Biotechnology, Health Care
View all alternatives

FAQ About Altay Therapeutics

Unlocking Transcription Factors to Address Unmet Medical Need
Altay Therapeutics was founded in 2019.
Altay Therapeutics is headquartered in San Francisco, United States.
Altay Therapeutics operates in Biotechnology, Health Care, Health and Wellness, Life Sciences and Pharmaceutical. Its work centres on small molecule drugs, drug development, transcription factors and chronic illnesses. Its customers include Patients with FSHD, Cancer patients and Patients with chronic inflammatory diseases.
Altay Therapeutics has a B2B business model. Its revenue comes from Licensing, Performance Based and Product Sales.
Altay Therapeutics has approximately 6 employees.
Altay Therapeutics has completed 7 funding rounds, raising a total of $3.37M. The latest funding stage is Seed.
Altay Therapeutics offers: Development of oral transcription factor inhibitors, Drug discovery and development, Precision medicine for underserved diseases.
Top alternatives and competitors to Altay Therapeutics include Amira Pharmaceuticals, Orbit Discovery, Reborna Biosciences, Inc., Flare Therapeutics, QUANTRO Therapeutics GmbH. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Altay Therapeutics and Amira Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Altay Therapeutics, https://bouncewatch.com/company/altay-therapeutics, updated 18 July 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout